Mironid

For patients with autosomal dominant polycystic kidney disease (ADKPD), abnormalities in two different genes – PKD1, which accounts for around 78% of cases, and PKD2, which accounts for around 15% – d

ReCode Therapeutics , on track with its plan to take its two lead programs into the clinic this year, announced on 19 September that it raised another $50m in series B venture capital, bringing the ro

Scotland's Mironid is moving from discovery into drug development, armed with fresh venture capital from Roche Holding AG and a promising candidate that could shake up the autosomal dominant polyc